{
    "2019-01-27": [
        [
            {
                "time": "2018-01-27",
                "original_text": "利妥昔首仿将上市，国内生物类似药进度盘点【周观点|长江医药0127】",
                "features": {
                    "keywords": [
                        "利妥昔",
                        "首仿",
                        "生物类似药",
                        "进度",
                        "长江医药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-27",
                "original_text": "生物仿制药重磅利好！这家公司即将拿到首个批文，还有一批在路上",
                "features": {
                    "keywords": [
                        "生物仿制药",
                        "利好",
                        "公司",
                        "首个批文",
                        "复星医药"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-27",
                "original_text": "审批新规首个生物仿制药即将获批，复星医药旗下复宏汉霖抢得头筹",
                "features": {
                    "keywords": [
                        "审批新规",
                        "生物仿制药",
                        "复星医药",
                        "复宏汉霖",
                        "头筹"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-27",
                "original_text": "首个生物仿制药即将获批 复宏汉霖抢得头筹",
                "features": {
                    "keywords": [
                        "生物仿制药",
                        "获批",
                        "复宏汉霖",
                        "头筹"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-27",
                "original_text": "公募老将选股思路延续 高ROE成为首要标准",
                "features": {
                    "keywords": [
                        "公募",
                        "选股思路",
                        "高ROE",
                        "首要标准"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "全行业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-27",
                "original_text": "【中泰一周微视】钢铁/银行/建材/地产/化工/医药/零售/通信/军工",
                "features": {
                    "keywords": [
                        "钢铁",
                        "银行",
                        "建材",
                        "地产",
                        "化工",
                        "医药",
                        "零售",
                        "通信",
                        "军工"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "多行业"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}